Sanofi SA
SNY:NYSE
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
| 48.69 | 0.00 0.00% | 3.47% | 1,123 | 1.4M |
Market data is delayed by at least 20 minutes.
Latest News Headlines for Sanofi SA
NBA Family, American Diabetes Association, and Sanofi US Tip Off 2013 Dribble To Stop Diabetes Awareness Campaign
The National Basketball Association (NBA), the Women's National Basketball Association (WNBA), and the NBA Development League, in collaboration with the American Diabetes Association and Sanofi US, today announced the tip-off of the 2013 Dribble to Stop Diabetes initiative, a national campaign designed to encourage fans to live an active, healthy lifestyle and raise awareness about type 2 diabetes prevention and management, along with the potentially serious health complications that can be associated with the disease.
Relatively Good Performance Detected in Shares of Forest Laboratories in the Pharmaceuticals Industry (FRX, MRK, SNY, MDCO, SLXP)
Here are the top 5 stocks in the Pharmaceuticals industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming. This is what we found:
Watch for Continued Gains in Shares of Sanofi-Aventis (SNY)
View more recent headlinesSanofi-Aventis (NYSE:SNY) traded today at a new 52-week high of $49.28. So far today approximately 801,000 shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares.
Over the past year, Sanofi-Aventis has traded in a range of $33.03 to $49.28 and is now at $49.01, 48% above that low. Over the last five market days, the 200-day moving average (MA) has gone up 0.5% while the 50-day MA has advanced 0.8%.
Company Background
Sanofi SA, formerly Sanofi-Aventis, is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi focuses on the field of healthcare with six growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets and animal health. Sanofi has a portfolio of prescription drugs, vaccines, generics and consumer healthcare products. In December 2011, Sanofi announced that it completed the divestiture of its dermatology business, Dermik, to Valeant Pharmaceuticals International, Inc. The Company is active domestically and abroad, including other European countries, North and Latin Americas, Asia, Africa and Middle East. As of January 31, 2012, the Company's major shareholder was L'oreal with a stake of 8.82%.
Bid/Size -- / -- | Ask/Size -- / -- |
Price Open 0.00 | Previous Close 48.69 |
Day High 0.00 | Day Low 0.00 |
52wk High/Date 49.28 / 1/11/2013 | 52wk Low/Date 33.03 / 6/1/2012 |
% off 52wk High -1.20% | % off 52wk Low 47.41% |
Beta (5 Yr) 0.9 | Market Capitalization 128.3B |
Shares Outstanding 2.6B | Volatility Avg 33.50 |
EPS(TTM) 3.03 | P/E Ratio 16.1x |
Dividend Announcement 2/9/2012 | Yield 3.47% |
Ex-Date 5/7/2012 | Date of Record 5/9/2012 |
Payable 1.6892 - ANN | Payable Date 5/30/2012 |
Last Trade as of 1/14/2013 4:03 PM ET | |
SNY Sanofi SA vs. Peers
| Peers | |
|---|---|
SNY Sanofi SA | 2.76% |
Abbott Laboratories | 6.45% |
Bristol Myers Squibb Co. | 5.00% |
Eli Lilly & Co. | 7.06% |
Merck & Co., Inc. | 5.86% |
SNY Sanofi SA | 3.47% |
Abbott Laboratories | 1.68% |
Bristol Myers Squibb Co. | 4.09% |
Eli Lilly & Co. | 3.71% |
Merck & Co., Inc. | 3.97% |
SNY Sanofi SA | 0.00% |
Abbott Laboratories | 0.00% |
Bristol Myers Squibb Co. | 0.00% |
Eli Lilly & Co. | 0.00% |
Merck & Co., Inc. | 0.00% |